gi-6207
Biologicalexperimental
Clinical trial activity
10 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
9
Phase 3
0
Phase 4
0
Earliest trial started Mar 13, 2009 (NCT00924092)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Carcinoma, Hepatocellular · Phase 1/Phase 2
- Carcinoma, Squamous Cell · Phase 1/Phase 2
- Carcinoma, Transitional Cell · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Head and Neck Neoplasms · Phase 1
- Lung Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 1
- Thyroid Neoplasms · Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
Mechanism of action
- Carcinoembryonic antigen-related cell adhesion molecule 5Immunity, active
CEACAM5 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gi-6207
- gi-6207
- yeast-cea vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03554109 | Phase 2 | Sep 30, 2018 | NantWorks |
| NCT03563144 | Phase 2 | Aug 31, 2018 | NantWorks |
| NCT03586869 | Phase 1/Phase 2 (Phase 2) | Jul 28, 2018 | NantWorks |
| NCT03563170 | Phase 1/Phase 2 (Phase 2) | May 25, 2018 | NantWorks |
| NCT03563157 | Phase 1/Phase 2 (Phase 2) | May 25, 2018 | NantWorks |
| NCT03387085 | Phase 1/Phase 2 (Phase 2) | Mar 16, 2018 | NantWorks |
| NCT03387111 | Phase 1/Phase 2 (Phase 2) | Jan 13, 2018 | NantWorks |
| NCT03197571 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2017 | NantWorks |
| NCT01856920 | Phase 2 | Mar 4, 2013 | National Cancer Institute (NCI) |
| NCT00924092 | Phase 1 | Mar 13, 2009 | National Cancer Institute (NCI) |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NantWorks | For profit | 8 | 8 | 1 | 2017 |
| National Cancer Institute (NCI) | Government | 2 | 2 | 2 | 2009 |
2 organizations
Page 1 / 1